THOMAS JAMES DOYLE - 07 Feb 2022 Form 3 Insider Report for Kura Oncology, Inc. (KURA)

Role
SVP, Finance & Accounting
Signature
Teresa Bair, Attorney-in-fact for Thomas Doyle
Issuer symbol
KURA
Transactions as of
07 Feb 2022
Net transactions value
$0
Form type
3
Filing time
09 Feb 2022, 16:48:19 UTC
Next filing
31 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KURA Common Stock 6,610 07 Feb 2022 Direct F1
holding KURA Common Stock 500 07 Feb 2022 spouse's 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KURA Option to purchase common stock 07 Feb 2022 Common Stock 75,000 $21.54 Direct F2
holding KURA Option to purchase common stock 07 Feb 2022 Common Stock 13,219 $14.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26.
F2 1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter.
F3 This option vests in 48 equal monthly installments commencing on the grant date.